Ocular Therapeutix, Inc.
OCUL
$9.16
-$0.12-1.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.81% | -22.43% | -5.71% | -18.14% | -27.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.81% | -22.43% | -5.71% | -18.14% | -27.59% |
| Cost of Revenue | 53.09% | 24.10% | 40.18% | 74.62% | 99.99% |
| Gross Profit | -69.82% | -55.72% | -70.71% | -184.14% | -358.64% |
| SG&A Expenses | 19.96% | 17.58% | 27.63% | 33.91% | 25.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.55% | 21.61% | 35.52% | 57.99% | 60.84% |
| Operating Income | -46.03% | -36.31% | -49.35% | -93.87% | -102.16% |
| Income Before Tax | -38.34% | -33.62% | -90.22% | -54.91% | 1.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.34% | -33.62% | -90.22% | -54.91% | 1.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.34% | -33.62% | -90.22% | -54.91% | 1.23% |
| EBIT | -46.03% | -36.31% | -49.35% | -93.87% | -102.16% |
| EBITDA | -46.27% | -36.41% | -50.16% | -96.31% | -105.02% |
| EPS Basic | -4.58% | -0.69% | -72.72% | -48.83% | 23.03% |
| Normalized Basic EPS | -4.57% | 0.55% | -72.69% | -85.85% | -35.26% |
| EPS Diluted | -5.26% | -0.69% | -72.73% | -48.83% | 22.64% |
| Normalized Diluted EPS | -4.57% | 0.55% | -72.69% | -85.85% | -35.26% |
| Average Basic Shares Outstanding | 32.29% | 32.68% | 10.14% | 4.08% | 28.31% |
| Average Diluted Shares Outstanding | 32.29% | 32.68% | 10.14% | 4.08% | 28.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |